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A B S T R A C T   
Neurometabolic diseases (NMDs) are typically caused by genetic abnormalities affecting enzyme functions, 
which in turn interfere with normal development and activity of the nervous system. Although the individual 
disorders are rare, NMDs are collectively relatively common and often lead to lifelong difficulties and high so-
cietal costs. Neuropsychiatric manifestations, including ADHD symptoms, are prominent in many NMDs, also 
when the primary biochemical defect originates in cells and tissues outside the nervous system. ADHD symptoms 
have been described in phenylketonuria, tyrosinemias, alkaptonuria, succinic semialdehyde dehydrogenase 
deficiency, X-linked ichthyosis, maple syrup urine disease, and several mitochondrial disorders, but are probably 
present in many other NMDs and may pose diagnostic and therapeutic challenges. Here we review current 
literature linking NMDs with ADHD symptoms. We cite emerging evidence that many NMDs converge on 
common neurochemical mechanisms that interfere with monoamine neurotransmitter synthesis, transport, 
metabolism, or receptor functions, mechanisms that are also considered central in ADHD pathophysiology and 
treatment. Finally, we discuss the therapeutic implications of these findings and propose a path forward to in-
crease our understanding of these relationships.   
1. Introduction 
The current concept of Attention-Deficit/Hyperactivity Disorder 
(ADHD) has a long history. During the last century, the defining symp-
toms of this disorder have been attributed to various causes, ranging 
from a “defect of moral control” (Still, 2006) to postencephalitic brain 
damage, environmental agents including pre-and postnatal malnutri-
tion, toxic agents or (mainly) a genetic predisposition (Faraone et al., 
2015). According to the predominant current view, ADHD symptoms are 
regarded as dimensional traits due to the concerted actions of many 
common and rare genetic variants in interaction with multiple envi-
ronmental factors. Although the majority of ADHD cases may fit into this 
polygenic risk model, with multiple additive genetic and environmental 
factors, it is also known that brain injuries, rare Mendelian diseases, and 
chromosomal aberrations can produce clinical symptoms that are very 
similar to or even indistinguishable from “classical” ADHD; the term 
“attention-deficit/hyperactivity syndrome” might be appropriate for 
such cases. As early recognition of such secondary cases of ADHD or 
other ADHD-mimicking conditions may have important clinical impli-
cations, clinicians need to be aware of these conditions. Here we present 
an updated overview of (rare) inherited metabolic disorders that show 
ADHD-like symptoms. We further describe possible neurochemical 
mechanisms for these comorbidities and their clinical and research im-
plications. In this context, we define neurometabolic disorders (NMDs) 
as inherited conditions that produce biochemical aberrations due to the 
complete or partial inactivation of defined enzymes or metabolite 
transporters. This excludes common genetic variants/polymorphisms, 
regulatory variants or variants in other protein targets, or variants with 
unknown or less established functions. 
In an exploratory literature search, we identified two recent 
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systematic reviews that have documented the clinical associations of 
ADHD and neurometabolic diseases (NMDs) (Instanes et al., 2018; Si-
mons et al., 2017). The current review aimed to describe possible shared 
and unique pathophysiological mechanisms that may explain such as-
sociations. In addition to the ten distinct NMDs that were the focus in 
these reviews (Table 1a), we conducted an additional literature search to 
identify additional studies published up until august 2021. For this 
purpose, we searched the electronic database PubMed (March and 
August 2021) using a combination of the following keywords: (1) 
“ADHD, Attention-Deficit/Hyperactivity Disorder, hyperactive or inat-
tention, and (2) neurometabolic disorder(s), NMDs, inborn errors of 
metabolism or neurometabolism”. In total, we identified 376 unique 
publications, 247 of which were considered relevant. We further 
selected articles focusing on mechanisms at the molecular genetics, 
neurochemical, metabolomic, proteomic, cellular, and organisms’ level. 
In contrast to the clinical and epidemiological literature summarized by 
Simons and Instanes (Instanes et al., 2018; Simons et al., 2017), our 
literature search revealed an extremely heterogeneous research field, 
with different research designs and little consensus regarding reporting 
practices. For this reason, it was considered unsuitable for a systematic 
review or meta-analysis. Instead, we present a targeted overview of 
what at this moment is considered the most established and promising 
mechanistic hypothesis explaining the associations of ADHD and some 
well-characterized NMDs. An overview of prevalence, pattern of inher-
itance, and pathophysiology of well documented NMDs is presented in 
Table 1a. Likewise, Table 1b provides a representative overview of re-
ported neuropsychiatric disorders and symptoms, with an emphasis of 
psychiatric and neuropsychological manifestations. Both tables are 
based on recent reviews (when possible) or original case reports. 
Notably, the tables do not intend to provide an exhaustive overview of 
all reported disorders or ADHD-related symptoms. Supplementary 
Table 1 provides a more detailed summary of the literature cited in 
Table 1b. Each of the NMDs is briefly introduced, with an emphasis on 
biochemical mechanisms. We identify common and converging evi-
dence linking NMDs with altered central nervous system (CNS) neuro-
transmitter functions and cellular metabolism and the implications of 
these findings for brain functions and ADHD symptoms. We also sum-
marize the clinical implications of these observations and point to 
several knowledge gaps that need to be addressed in future research. 
2. Biological mechanisms for ADHD symptoms 
ADHD–like symptoms have been observed in several metabolic dis-
orders. For nearly a century, phenylketonuria (PKU) and related amino 
acid (AA) metabolism disorders have been considered model diseases to 
understand how peripheral metabolic defects may affect brain functions. 
Here we briefly review the neuropsychiatric manifestations of these 
conditions, with an emphasis on ADHD-like traits. 
In PKU, an elevated risk for attentional disorders remains even after 
recommended dietary treatment (Ashe et al., 2019). Similar attentional 
difficulties (Pohorecka et al., 2012) and problems related to working 
memory (van Ginkel et al., 2016) are described in treated Tyrosinemia 
type 1 (HT1). Succinic semialdehyde dehydrogenase (SSADH) defi-
ciency is characterized by a wide range of cognitive and somatic diffi-
culties, including ADHD (DiBacco et al., 2019), hyperactivity, and 
impulsivity (Gibson et al., 2003). Maple syrup urine disease (MSUD) 
patients also have different comorbid neuropsychiatric conditions, 
including a high incidence of ADHD (Muelly et al., 2013). ADHD is 
probably the most common neurodevelopmental disorder in X-linked 
ichthyosis (XLI), with most patients having an inattentive presentation 
(Kent et al., 2008). Moreover, executive function and attention deficits 
have been found in Mitochondrial encephalomyopathy, lactic acidosis 
and stroke-like episodes (MELAS) syndrome (Kraya et al., 2019). Simi-
larly, Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) 
Table 1a 
Overview of prevalence, pattern of inheritance, and pathophysiology for selected NMDs.  
Disease Prevalence Inheritance pattern Pathophysiology Reference(s) 
Phenylketonuria (PKU) 1:8900-11226 
(Caucasians) 
1:13500− 19000 (US) 
Autosomal recessivePAH 
mutations 
PAH deficiency causes hyperphenylalaninemia (Ashe et al., 2019) 





FAH deficiency inhibits Tyr degradation and 
causes accumulation of fumarylacetoacetate 
and succinylacetone 
(Barone et al., 2020) 
Tyrosinemia Type 2 (HT2) <1:1 000 000 Autosomal recessiveTAT 
mutations 
TAT deficiency causes impaired breakdown 
and accumulation of Tyr 
(Wendel, 2010) 




4-HPPD deficiency causes impaired breakdown 
and accumulation of Tyr 
(Heylen et al., 2012) 




HGD deficiency causes impaired Phe/Tyr 
breakdown and accumulation of HGA 








SSADH deficiency causes impaired oxidation of 
SSA and accumulation of GHB/GABA 
(Didiasova et al., 2020) 




BCKDHB, DBT mutations 
BCKD complex deficiency cause accumulation 
of BCAAs (Iso, Val, Leu) and BCKAs 
(α-ketoisocaproic acid, α-keto-3-methylvaleric 
acid, and α-ketoisovaleric acid) 
(Strauss et al., 2020) 
X-linked ichthyosis (XLI) 1:1500− 6000 (males 
worldwide) 
X-linked recessiveSTS mutations STS deficiency causes impaired cleavage of 
sulfate groups from steroid hormones and 
sulfatases, and accumulation of CSO4/DHEAS 
(Hernandez-Martin et al., 
1999; Diociaiuti et al., 
2019) 
Mitochondrial encephalomyopathy 
lactic acidosis and stroke-like 
episodes (MELAS) syndrome 




(~90 % of cases) 
Decreased synthesis of ETC complex subunits; 
impaired mitochondrial energy production 
(El-Hattab et al., 2015) 
Mucopolysaccharidosis III (MPS III, 
Sanfilippo syndrome) 
0.3− 4.1:100 000 
(depending on subtype) 
Autosomal recessiveSGSH, 
NAGLU, chromosome 8p11.21 
(pericentromeric region), GNS 
mutations 
Deficiency of one of four enzymes causes 
impaired degradation of the 
glycosaminoglycan HS 
(Andrade et al., 2015) 
PAH (phenylalanine hydroxylase); FAH (fumarylacetoacetate hydrolase); TAT (tyrosine aminotransferase); 4-HPPD (4-hydroxypenylpyruvate dioxygenase); HGD 
(homogentisate 1,2-dioxigenase); HGA (homogentisic acid); SSA (succinic acid, succinate); BCKD (branched-chain a-keto acid dehydrogenase); BCAA (branched chain 
amino acids); BCKAs (branched chain keto-acids); STS (steroid sulfatase); CSO4 (cholesterol sulfate); DHEAS (dehydroepiandrosterone sulfate); ETC (electron 
transport chain); MT-TL1 (mitochondrially encoded tRNA leucine 1 (UUA/G); SGSH (N-sulfoglucosamine); NAGLU (N-Acetyl-Alpha-Glucosaminidase); GNS 
(glucosamine (N-acetyl)-6-sulfatase); HS (heparan sulfate). 
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may be mistaken for ADHD or autism spectrum disorder (ASD) since 
hyperactivity, impulsivity, and extreme restlessness are common (Wij-
burg et al., 2013). 
Most of the disorders are characterized by a range of other difficulties 
in addition to symptoms of ADHD. However, a high level of somatic and 
neuropsychiatric comorbidity is also in common ADHD without diag-
nosed metabolic diseases. Therefore, a broad characterization of clinical 
phenotypes in metabolic disorders and possible biochemical mecha-
nisms behind these may provide more insight into the heterogeneous 
comorbidity profiles in ADHD. A more detailed description of the bio-
logical and clinical characteristics of the disorders mentioned above is 
presented in the following sections of this review. As far as we know, 
there are no reports of ADHD-like symptoms in alkaptonuria (AKU) and 
only occasionally in a range of other metabolic disorders. Still, some of 
these disorders are briefly described as they could be interesting targets 
for future research. 
There is still limited knowledge about the precise molecular and 
cellular mechanisms underlying ADHD symptoms. Although recent ge-
netic studies (Demontis et al., 2019) in children and adults with ADHD 
have revealed strong associations with several genetic loci, genes, and 
pathways, a unifying model for the development of these symptoms is 
still lacking (Demontis et al., 2019; Rovira et al., 2020). Despite these 
limitations, several theories have gained experimental support during 
the past decades from different disciplines, including brain imaging, 
pharmacological, genetic, biochemical, and neuropsychological in-
vestigations. Briefly, such theories include altered neurotransmission 
and synaptic functions, disturbed brain energy homeostasis, or devel-
opmental delays of the nervous system. The latter hypothesis is 
supported by the identification of risk variants involved in neurotrophin 
release, neuronal migration, brain differentiation, and myelination 
(Demontis et al., 2019; Rovira et al., 2020). Importantly, these theories 
neither pretend to be universal nor mutually exclusive (Killeen, 2019; 
Tripp and Wickens, 2009). 
As the most effective pharmacological treatments used for ADHD all 
target catecholamine (dopamine and noradrenaline) neurotransmission, 
it has long been speculated that aberrations of these neurotransmitter 
pathways may be involved in the pathophysiology of ADHD. Thus, 
neurochemical alterations that affect monoamine neuromodulator 
functions are of particular relevance. As monoamine transmitters/neu-
romodulators are derived from aromatic AAs, it is not surprising that 
aromatic AA metabolism perturbations have been linked to brain 
dysfunction. Likewise, altered transport, metabolism, and functions of 
the amino acids glutamate, glycine, and gamma-aminobutyrate, the 
major excitatory and inhibitory transmitters in the CNS have received 
much attention. Alternatively, it has been suggested that ADHD symp-
toms derive from altered neuroenergetics (Reviewed by Killeen et al. 
(Killeen et al., 2013)). One such postulated energy deficiency may occur 
secondary to a catecholaminergic hypofunctionality that affects astro-
cyte metabolism; thus, linking the impaired energy metabolism hy-
pothesis with altered monoaminergic neurotransmission (Russell et al., 
2006). Furthermore, it is conceivable that other conditions involving 
altered astrocyte-neuronal metabolic coupling may influence energy 
homeostasis, cerebrovascular flow and neuronal activity at the neuro-
vascular unit. Thus, Locus coeruleus derived noradrenergic terminals 
innervate the microvascular compartment of the brain to modulate ox-
ygen and nutrient delivery in response to local neuronal activity (Bekar 
Table 1b 
Reported neuropsychiatric symptoms and disorders in selected NMDs. Dark green: high prevalence, reported across studies, and/or found in large cohorts 
(relative to reported cases of the NMD). Light green: low prevalence, documented but few case reports. White: not reported (in selected references). The findings are 
based on recent representative reviews (when possible) or original case reports. Supplementary Table 1 provides a more detailed summary of the literature cited in this 
table.  
*Psychosis, Schizophrenia. 
References for Table 1b. 
1 (Mainka et al., 2021), 2 (Aitkenhead et al., 2021), 3 (Yamada et al., 2021), 4 (Ashe et al., 2019), 5 (Bilder et al., 2017), 6 (Antshel, 2010), 7 (Barone et al., 2020), 8 
(van Vliet et al., 2019b), 9 (Garcia et al., 2017), 10 (van Ginkel et al., 2016), 11 (Pohorecka et al., 2012), 12 (Barroso et al., 2020), 13 (Blundell et al., 2018), 14 (Gokay 
et al., 2016), 15 (Scott, 2006), 16 (Ellaway et al., 2001), 17 (Kisa et al., 2021), 18 (Davison et al., 2018), 19 (Pearl et al., 2021), 20 (DiBacco et al., 2019), 21 (Knerr 
et al., 2008), 22 (Gibson et al., 2003), 23 (Pearl et al., 2003b), 24 (Gibson et al., 1997), 25 (Medina et al., 2021), 26 (Strauss et al., 2020), 27 (Abi-Warde et al., 2017), 
28 (Muelly et al., 2013), 29 (Diociaiuti et al., 2019), 30 (Rodrigo-Nicolas et al., 2018), 31 (Chatterjee et al., 2016), 32 (Kent et al., 2008), 33 (Moore et al., 2020), 34 
(Kraya et al., 2019), 35 (El-Hattab et al., 2015), 36 (Anglin et al., 2012), 37 (Neargarder et al., 2007), 38 (Hoffmann et al., 2020), 39 (Kong et al., 2020), 40 (Andrade 
et al., 2015), 41 (Wijburg et al., 2013), 42 (Valstar et al., 2011), 43 (Heron et al., 2011), 44 (Bax and Colville, 1995). 
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et al., 2012). Notably, catecholamine synthesis is expected to be sub-
saturated with oxygen under normoxic conditions (Rostrup et al., 2008), 
implicating that even mild hypoxia or ischemia might compromise 
neurotransmitter synthesis. However, although hemodynamic differ-
ences and alterations in cerebrovascular flow are noted in ADHD pa-
tients and with ADHD medication in many studies, it is still unclear if 
this is associated with dysregulation of the neurovascular unit. 
Early candidate gene studies with small sample sizes and targeted 
genotyping provided some support for the involvement of monoamine 
transporters, receptors, and enzymes as risk factors for ADHD and other 
neuropsychiatric disorders. However, few of these early association and 
linkage findings have been confirmed with improved technology and 
increased sample sizes. In the largest ADHD genome-wide genetic 
association study (GWAS) published to date, only one of the previously 
proposed ADHD candidate genes showed some association with ADHD 
(SLC9A9, P = 3.4 × 10− 4)-3) and also with body mass index (P = 1.63 ×
10-5). The authors suggested that dopaminergic neurotransmission, 
partially through DARPP-32-dependent signaling and involving the 
putamen, is involved in the genetic overlap between ADHD and obesity 
measures (Mota et al., 2020). Overall, the analysis of common genetic 
variants indicates that ADHD is very polygenic, possibly involving many 
different biological mechanisms, where genes involved in monoamine 
signaling only account for a small fraction. Although analyses of com-
mon variants do not support a primary role of the “usual suspects” in 
disease etiology for most patients, many ADHD cases with coding vari-
ants affecting monoamine functions have been reported (Hansen et al., 
Fig. 1. Relationship between CNS monoamine synthesis, NO signaling, and aromatic amino acid transport. Aromatic amino acids are precursors of 
monoamines. The first and rate-limiting step in their synthesis is catalyzed by aromatic amino acid hydroxylases (AAAHs) (A, B), tyrosine hydroxylase (TH, EC 
1.14.16.2; tyrosine 3-monooxygenase), and tryptophan hydroxylase 1 and 2 (TPH1, TPH2, EC 1.14.16.4). Therefore, the brain synthesis of these neurotransmitters 
relies on the circulatory supply of precursory amino acids (D) within levels that do not compromise the enzymatic output of biosynthesis and metabolism. (A) shows 
dopamine (DA) and norepinephrine (NE) synthesis, vesicular storage, release, reuptake and metabolism. TH is the first and rate-limiting enzyme in the biosynthesis of 
catecholamines and is regulated through many mechanisms including reactive oxygen species (ROS) and nitric oxide (NO) mediated signaling. ROS may stimulate 
p38 Mitogen Activated Protein Kinase (p38MAPK) activation, which through activation of MAPK activated protein kinase 2 (MK2) can stimulate TH through Ser19 
phosphorylation. NO can activate cGMP synthesis through activation of soluble guanylate cyclase (sGC), which leads to activation of protein kinase G (PKG) and 
activation of TH through Ser40 phosphorylation. NO may also lead to S-nitrosylation of cysteines in TH or nitration via formation of peroxynitrate in reaction with 
superoxide. (B) shows serotonin (5-HT) synthesis, vesicular storage, release, reuptake, and metabolism. TPH2 catalyzes the first and rate-limiting step in the 
biosynthesis of 5-HT and is regulated through many mechanisms, including ROS or NO. TH and TPHs also rely on the cofactor tetrahydrobiopterin (BH4, see also 
Fig. 2) for their catalysis, which must be synthesized and regenerated locally in the monoamine producing cells by specific enzymes. In the synthesis pathways 
tyrosine (Tyr) or tryptophan (Trp) are hydroxylated by TH or TPH2 to Dopa or 5-HTrp, respectively. Dopa and 5-HTrp are subsequently decarboxylated by aromatic 
amino acid decarboxylase (AADC), yielding DA or 5-HT, respectively. The monoamines are transported into storage vesicles by the vesicular monoamine transporter 
2 (VMAT2) for release. In the case of NE, vesicular DA is hydroxylated by dopamine β-hydroxylase (DBH) within the vesicles in a reaction relying on ascorbate and 
molecular oxygen. In the brain, catecholamines and serotonin are synthesized and released from neurons originating in the midbrain and extending to specific brain 
areas where they exert their neuromodulator effects through multiple receptor types. Much of monoamine transmission is of the so-called volume transmission type, 
where their diffusion-mediated spread is controlled by reuptake transporters like serotonin (SERT), norepinephrine (NET), and dopamine (DAT) transporters. The 
DAT and NET are major targets for the most common ADHD medication. The monoamines are metabolized by monoamine oxidases (MAOs, EC 1.4.3.4), cate-
cholamine O-methyltransferase (COMT, EC 2.1.1.6), and aldehyde dehydrogenase. The main metabolites measured in plasma and the cerebrospinal fluid (CSF) are 
homovanillic acid (HVA) for DA, 3-methoxy-4-hydroxyphenyl-glycol for CNS NE, vanillomandelic acid for peripheral NE, and 5-hydroxy indole acetic acid (5-HIAA) 
for 5-HT. (C) shows nitric oxide (NO) synthesis and its downstream effector mechanisms through second messenger cGMP signaling, protein S-nitrosylation, and via 
the reaction between NO and superoxide (O2− ) to form the reactive peroxynitrite, which may react with proteins and lipids and oxidize BH4. (D) shows transport of 
aromatic amino acids (Phe, Tyr, and Trp) across the blood brain barrier of a microvascular capillary. The transporters involved at the luminal (blood) and abluminal 
(brain) side are shown. 
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2014; McKinney et al., 2008). Due to their low population frequencies, it 
is difficult to determine the role of such rare coding variants in ADHD 
etiology. However, as their effect sizes may be much larger than for 
common variants studied in GWAS, genetic alterations in 
monoamine-related genes can directly or indirectly contribute to this 
disorder. Thus, monoamines are still considered central in the concep-
tualization of ADHD pathophysiology and intervention strategies. The 
following section provides a brief review of current knowledge on 
monoamine synthesis and regulation and how this may be linked to 
ADHD pathophysiology. 
3. Monoamines in ADHD and mechanisms for disturbed 
synthesis in NMDs 
3.1. Monoamine synthesis and regulation 
The brain synthesis of the monoamine neurotransmitters dopamine, 
norepinephrine, and serotonin relies on the circulatory supply of pre-
cursory AAs (Fig. 1). Below we describe several NMDs where the balance 
of aromatic AAs is disturbed, leading to dysregulation in monoamine 
homeostasis. We also describe disorders in the metabolism of the 
enzyme cofactor tetrahydrobiopterin (BH4), which are also associated 
with disturbances in monoamine homeostasis (Figs. 1 and 2). Duration 
of monoamine neurotransmission is largely controlled by reuptake 
transporters (Fig. 1) and as briefly introduced in Section 2, the dopa-
mine- and norepinephrine transporters are major targets for the most 
common ADHD medication. Thus, transporter activity, and the presyn-
aptic quantal release, are ways to control monoamine signaling spread 
and duration. However, monoamines first need to be synthesized, and it 
is becoming clear that their synthesis rate is closely co-regulated with 
neurotransmission (Lindgren et al., 2001; Salvatore et al., 2016). 
Downstream effects of the released monoamines are mediated through a 
range of receptors that, except for 5-hydroxytryptamine (5-HT) type 3, 
are G-protein coupled receptors (GPCRs) that act through stimulation or 
inhibition of second messenger systems. These effector systems are 
outside the scope of this review and will not be discussed in further 
detail. 
Inhibitors of monoamine metabolism, particularly the monoamine 
oxidases (MAO-A and -B), are used to increase the levels of these 
transmitters. Inhibitors of MAO-A increase 5-HT levels more than MAO- 
B, whereas MAO-B inhibitors have larger effects on DA metabolism 
(Edmondson and Binda, 2018). Increased expression of MAO-A may 
contribute to the development of neuropsychiatric disorders, such as 
depression and anxiety (Finberg and Rabey, 2016). On the other hand, 
low expression of MAO-A may predispose to increased aggression 
(McDermott et al., 2009). Notably, MAO deficiency is more often 
Fig. 2. Tetrahydrobiopterin synthesis and 
regeneration. (6R)-5,6,7,8-Tetrahydrobiopteri 
n (BH4) is synthesized from GTP by the en-
zymes GTP cyclohydrolase I (GTPCH), 6-Pyro-
voyltetrahydropterin synthase (PTPS), and 
Sepiapterin reductase (SR). BH4 is a cofactor of 
the nitric oxide synthase and is used by the 
aromatic amino acid hydroxylases (AAAHs), 
forming tetrahydrobiopterin 4a-carbinolamine, 
which will spontaneously dehydrate to 
quinonoid-dihydrobiopterin (q-BH2) or cata-
lyzed by pterin carbinolamine dehydratase 
(PCD). BH4 can be regenerated from q-BH2 by 
the NADH-dependent dihydrobiopterin reduc-
tase (DHPR). Alternatively, q-BH2 (or BH4) 
may oxidize into 7,8-Dihydrobiopterin, which 
can be regenerated to BH4 by the NADPH- 
dependent Dihydrofolate reductase (DHFR). 
BH4 can also be synthesized from sepiapterin 
via 7,8-Dihydrobiopterin by SR (referred to as 
the salvage pathway). Different enzyme de-
ficiencies leading to BH4-deficiency and their 
association with hyperphenylalaninemia (*), 
catecholamine deficiency (¶), or serotonin 
deficiency (§) are also shown. The correspond-
ing gene names of the enzymes are shown in 
italics.   
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observed in men since both MAO genes are located on the X-chromo-
some. For instance, the extremely rare Brunner syndrome is character-
ized by a selective deficiency of enzymatic MAO-A activity and 
impulsive aggression in males, not unlike symptoms that may also be 
observed in ADHD patients (Brunner et al., 1993). 
3.1.1. Regulation of catecholamine synthesis 
Regulation of tyrosine hydroxylase (TH) abundance and activity are 
major mechanisms to control catecholamine synthesis, and many 
different regulatory mechanisms have been reported (Dunkley and 
Dickson, 2019; Tekin et al., 2014). In addition to feedback inhibitory 
coordination of catecholamines to the active site iron of TH (Andersson 
et al., 1988), protein phosphorylation of N-terminal Ser/Thr residues 
(notably Ser19, Ser31, and Ser40) are well described regulatory tar-
geting of TH to modulate its activity, protein-protein interactions, 
localization, and stability. The regulation of TH by signaling pathways 
may open up new therapeutic options to modulate catecholamine ho-
meostasis. Thus, Ser40 phosphorylation is a major regulatory site to 
modulate TH activity as it releases bound inhibitory catecholamines 
(Almas et al., 1992; Andersson et al., 1992). Cyclic nucleotide signaling 
pathways (e.g., protein kinase A (PKA) and nitric oxide (NO)/cyclic 
guanosine monophosphate (cGMP) signaling 4.1, Fig. 1) are major 
signaling pathways that target this site as well as multiple stress and 
mitogen signaling regulated kinases (Almas et al., 1992; Rodri-
guez-Pascual et al., 1999; Thomas et al., 1997; Toska et al., 2002). 
Although cyclic adenosine monophosphate (cAMP) signaling is a key 
pathway both pre- and post-synaptic for catecholamine neurotransmis-
sion, different expression profiles of phosphodiesterases could provide 
opportunities for selective pharmacological targeting (Nishi et al., 2008; 
Sharma et al., 2021). 
Stress kinase signaling downstream of the p38 mitogen activated 
protein kinase (MAPK) can increase TH Ser19 phosphorylation (Fig. 1B), 
the main target for calcium/calmodulin-dependent protein kinase II 
(CaMKII). TH phosphorylation of Ser19 makes the enzyme available for 
binding and activation by the 14-3-3 proteins (Ghorbani et al., 2016; 
Itagaki et al., 1999), a conserved family of multi-functional Ser/Thr 
phospho-targeting proteins (Cornell and Toyo-Oka, 2017). Phosphory-
lation of TH, in particular on Ser40, increases the affinity for the BH4 
cofactor (Almas et al., 1992), whereas it has minor effects on its other 
substrates, oxygen and Tyr (Rostrup et al., 2008). In addition to its 
importance for catalysis, BH4 is essential in maintaining the active site 
iron in the catalytically competent Fe(II) state (Frantom et al., 2006). 
BH4 therapy has been suggested as an option to improve brain mono-
amine homeostasis in conditions where their synthesis is compromised 
and may even work synergistically with brain NO signaling and oxida-
tive stress (Evers et al., 2020). TH shows pronounced substrate inhibi-
tion for tyrosine (Tyr), particularly the human recombinant enzyme 
(Fossbakk et al., 2014). It is still unclear if this type of kinetics plays a 
role under normal conditions, although its importance for monoamine 
homeostasis has been postulated based on mathematical modeling (Best 
et al., 2009). However, at hypertyrosinemic conditions, as found in the 
tyrosinemias (Table 1a, Fig. 3), significantly impaired TH activity can be 
expected, and it could be speculated if this would perturb brain dopa-
mine or norepinephrine synthesis through substrate inhibition (Barone 
et al., 2020). 
3.1.2. Synthesis and regulation of serotonin 
In 2003, Walther et al. discovered that tryptophan hydroxylase 
(TPH) is encoded by two distinct genes, giving rise to two enzyme iso-
forms; TPH1 and TPH2 (Walther and Bader, 2003; Walther et al., 2003), 
which have different patterns of expression as well as kinetic and reg-
ulatory properties (McKinney et al., 2005). TPH1 is mainly expressed in 
peripheral tissues and in the pineal gland, where it contributes to the 
biosynthesis of melatonin (Amireault et al., 2013; Cote et al., 2003), 
while TPH2 is exclusively expressed in the rest of the central nervous 
system (Malek et al., 2005) and essential for 5-HT biosynthesis in the 
brain. Both TPH1 and 2 can bind and hydroxylate phenylalanine (Phe) 
and Tyr with different catalytic efficiencies than tryptophan (Trp) 
(McKinney et al., 2005). Thus, under pathological conditions where Phe 
and Tyr are elevated, both peripheral and brain serotonin synthesis can 
be affected. TPH1 is more strongly inhibited by Phe than TPH2 
(McKinney et al., 2005), whereas TPH2 is shown to be significantly 
inhibited by Tyr at levels mimicking that found in tyrosinemia patients 
(below) (Barone et al., 2020). Dysregulation of serotonin levels in 
different tissues is believed to have an essential role in the development 
of several disorders, including osteoporosis (Inose et al., 2011), carci-
noid syndrome (Crane et al., 2015; Hallen, 1964; Macdonald et al., 
1958), pulmonary arterial hypertension (Morecroft et al., 2007), and 
neuropsychiatric disorders, such as ADHD, autism, schizophrenia 
(Jacobsen et al., 2015; Watanabe et al., 2007), anxiety, and depression 
(Matthes et al., 2010; Zhang et al., 2005). 
The mechanism behind the putative contribution of TPH to the 
pathogenesis of neuropsychiatric disorders such as ADHD (Halmoy 
Fig. 3. Liver metabolism of phenylalanine and tyrosine. The figure shows 
the enzymes involved in the catabolism of phenylalanine (Phe) and tyrosine 
(Tyr) to fumarate and acetoacetate and the diseases associated with deficiencies 
in the enzymes. Phe and Tyr from the circulation are in exchange with Phe and 
Tyr of hepatocytes in the liver. Phenylalanine hydroxylase (PAH) catalyzes the 
tetrahydrobiopterin-dependent conversion of Phe to Tyr. PAH deficiency is 
associated with phenylketonuria (PKU). Tyrosine aminotransferase (TAT) 
converts Tyr to p-hydroxyphenylpyruvate through a reversible transfer of the 
amino group to 2-oxoglutarate. TAT deficiency is associated with Tyrosinemia 
type 2. The p-Hydroxyphenylpyruvate dioxygenase (HPPD) catalyzes oxidative 
decarboxylation to form homogentisate. HPPD is also inhibited by nitisinone, 
and HPPD deficiency is associated with Tyrosinemia type 3. The next step in-
volves oxygenation by Homogentisate 1,2-dioxygenase (HGD) to form 4-maley-
lacetoacetate, and HGD deficiency is associated with Alkaptonuria. 4- 
maleylacetoacetate spontaneously rearranges into 4-fumarylacetoacetate, but 
the reaction is accelerated by Maleylacetoacetate isomerase (MAAI). The final 
reaction converting 4-fumarylacetoacetate to fumarate and acetoacetate is 
catalyzed by Fumarylacetoacetate hydrolase (FAH), which is deficient in 
Tyrosinemia type 1. 
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et al., 2010; Porter et al., 2008) and its comorbidities, e.g., obesity and 
depression (Cortese and Tessari, 2017; Crane et al., 2015) is not fully 
understood. Several studies have indicated that the expression of TPH1 
might have a crucial role in brain development (Cote et al., 2007); a 
study on mice showed the involvement of TPH1 in regulating 5-HT 
levels in the brain during late developmental stages, but not in the 
adult animal (Nakamura et al., 2006). Altered fetal 5-HT levels may 
result in delayed brain development, which has been linked to ADHD in 
brain imaging studies (Faraone et al., 2015; Klein et al., 2017). 
Another study, on human subjects, found that TPH1 mutations that 
reduce maternal 5-HT production may cause impairment in brain 
development and increase the risk of having ADHD in offspring (Halmoy 
et al., 2010). In addition, coding variants in TPH2 have been associated 
with a deficiency of brain serotonin (McKinney et al., 2008). Studies 
using knockout mice lacking Tph2 found, as expected, low levels of 
central serotonin and an increase of symptoms of anxiety and depression 
(Sachs et al., 2015; Waider et al., 2017). As serotonin and other mono-
amines also are modulators of synaptic plasticity and brain development 
(Kandel et al., 2014), alterations of these monoamines may affect brain 
functions at multiple levels. 
3.1.3. Synthesis and recycling of tetrahydrobiopterin 
Several NMDs are caused by cofactor deficiencies, rather than lack of 
enzyme protein. All the aromatic AA hydroxylases (AAAHs) rely on the 
fully reduced cofactor BH4 ((6R)-5,6,7,8-tetrahydrobiopterin) and mo-
lecular oxygen for hydroxylation of the respective AA substrate. Syn-
thesis and regeneration of BH4 are therefore crucial for the synthesis of 
related monoamines. BH4 is synthesized from guanosine triphosphate 
(GTP) in a three-step pathway via the enzymes GTP cyclohydrolase I 
(GTPCH), 6-pyruvoyltetrahydropterin synthase (PTPS), and sepiapterin 
reductase (SR). The hydroxylation reaction of the AAAHs generates the 
4a-carbinolamine form of BH4, which spontaneously or by pterin-4a- 
carbinolaminedehydratase (PCD) can be dehydrated to the quinoid 
form of dihydrobiopterin (q-BH2) that can be regenerated to BH4 by the 
NADH-dependent dihydropteridine reductase (DHPR). BH4 and q-BH2 
can be converted to 7,8-dihydrobiopterin (BH2) by different oxidation 
steps but may be regenerated to BH4 by NADPH-dependent dihy-
drofolate reductase (DHFR) (Thony et al., 2000) (Fig. 2). 
Several studies have described mutations in the enzymes that play a 
role in the biosynthesis and regeneration of BH4, which cause a shortage 
of this cofactor, and as a consequence, can contribute to the develop-
ment of hyperphenylalaninemia (PKU) (Scriver et al., 1987, 1994), 
characterized by a deficiency of phenylalanine hydroxylase (PAH, EC 
1.14.16.1) activity and a depletion of the neurotransmitters dopamine 
and serotonin, brain degeneration, and progressive neuropsychiatric 
impairment (Pascucci et al., 2002; Pilotto et al., 2019; Porta et al., 
2015). Other findings suggest that reduced levels of BH4 in the cere-
brospinal fluid are linked to the development of several neuropsychi-
atric disorders, e.g., Parkinson’s disease, depression, Alzheimer’s 
disease (Thony et al., 2000), ADHD (Antshel, 2010; Antshel and 
Waisbren, 2003), and autistic disorders (Steiner et al., 2007). 
BH4 is also a cofactor for NO synthases 1-3 (NOS 1-3), of which NOS1 
is referred to as the neuronal isoform and the primary NOS expressed in 
the brain. Decreased NO metabolites have been found in CSF of patients 
with deficiencies in BH4 synthesis and regeneration (Zorzi et al., 2002), 
and oxidation of the cellular BH4 pool to BH2 is associated with 
increased uncoupling of NOS and formation of superoxide (O2-) (Crab-
tree et al., 2009). NO has pleiotropic effects (Fig. 1A); its main effector 
mechanism is thought to be the stimulation of soluble guanylate cy-
clases, leading to increased cGMP and thus downstream targeting of 
several protein kinases, phosphodiesterases, and ion channels (Hof-
mann, 2020). However, NO can also lead to post-translational modifi-
cation of amino acid residues in target proteins, i.e., nitrosylation of 
cysteine moieties or, via formation of peroxynitrite, nitration of tyro-
sine, tryptophan, and cysteine. These modifications may positively or 
negatively regulate the target proteins. Finally, NO may inhibit 
heme-containing proteins by binding to heme molecules (sGC being a 
notable exception). 
Altered NOS signaling has been linked to several neuropsychiatric 
disorders, including ADHD. Interestingly, NOS1 is upregulated by 
methylphenidate treatment (Cavaliere et al., 2012) and it was recently 
reported that ADHD is accompanied with peripheral changes in the NO 
pathway (Jansen et al., 2020; Kittel-Schneider et al., 2015), suggesting 
that compromised NOS signaling may be involved in ADHD pathogen-
esis (Freudenberg et al., 2015). Alterations of NO signaling in the locus 
coeruleus are also postulated to underly attention deficits observed in 
patients with argininosuccinate lyase (ASL, EC 4.3.2.1) deficiency 
(Lerner et al., 2019). Thus, it was found that TH and catecholamine 
levels were decreased by argininosuccinate lyase (ASL) knock-out 
through decreased cAMP-response-element-binding protein (CREB) 
mediated transcriptional control and TH nitrosylation. ASL is involved 
in the urea cycle, as well as in the regeneration of arginine from 
citrulline, which is important for NO synthesis as L-arginine is the pri-
mary substrate of all NOS. 
3.2. Neurometabolic diseases affecting aromatic amino acid metabolism 
and transport 
The essential aromatic AAs Phe and Trp must be provided through 
food in sufficient amounts to support development, growth, and tissue 
homeostasis. It has recently become clear that the microbiome can also 
provide the host with essential AAs through in situ synthesis (Heinken 
et al., 2013). Still, a complete overview of the involved homeostatic 
mechanisms for AA tissue supply and in humans at different nutrient 
states is lacking. In typical Western protein-rich diets, tissue uptake and 
liver metabolism are the major drivers to maintaining plasma levels of 
aromatic AAs. Phe and Tyr are of particular relevance for 
catecholamine-related disorders, as they are precursors for the synthesis 
of dopamine, noradrenaline, and adrenaline. They are degraded to 
fumarate and acetoacetate through a common pathway. Deficiencies in 
enzymes of this pathway lead to pathological accumulation of Phe, Tyr, 
or metabolite intermediates, which influence brain monoamine syn-
thesis and can give rise to several neurocognitive deviations and ADHD 
symptoms (below). 
3.2.1. Liver metabolism of phenylalanine and tyrosine 
PAH catalyzes the first step converting Phe to Tyr and its activity is 
regulated through allosteric kinetics as well as through cell signaling 
(Flydal and Martinez, 2013). PAH is a member of the BH4-dependent 
AAAHs and the synthesis and regeneration of BH4 are necessary for PAH 
activity. Deficient PAH activity leads to severe hyperphenylalaninemia, 
referred to as PKU (OMIM 261600 and 261630), which if left untreated 
can lead to highly elevated serum Phe levels (several mM), compared to 
normal fasting levels around 60 μM. PKU is an autosomal recessive 
disorder with a prevalence of about 1:10 000 in Caucasians and there-
fore one of the most frequent inherited metabolic diseases (Ashe et al., 
2019). If left untreated, the high Phe levels can lead to severe cognitive 
dysfunctions, mainly through disturbed monoamine synthesis. Howev-
er, as it is difficult to maintain low circulating Phe levels. Treated PKU 
patients also commonly experience neuropsychiatric symptoms. High 
Phe-levels may compromise catecholamine and serotonin synthesis in 
the brain through interfering with AA transport across the blood-brain 
barrier (BBB) or by their effects on enzymes involved in their biosyn-
thetic pathways (Fig. 1 and see below) (Ashe et al., 2019). 
The tissue level of Tyr is maintained by protein recycling and by a 
balance between Phe hydroxylation and further degradation by the 
reversible, pyridoxal phosphate-dependent activity of Tyrosine Amino-
transferase (TAT; EC 2.6.1.5) (Fig. 3). TAT activity is deficient in 
Tyrosinemia Type 2 (HT2, OMIM 276600), giving rise to very high 
plasma levels of Tyr. The subsequent two steps, conversion of p- 
hydroxyphenylpyruvate to homogentisate and further to 4-maleylace-
toacetate are catalyzed by dioxygenase enzymes (HPPD and HGD), 
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whose activities are compromised in Tyrosinemia Type 3 (HT3, OMIM 
276710) and AKU (AKU, OMIM 203500), respectively (Fig. 3). The p- 
hydroxyphenylpyruvate dioxygenase (HPPD, EC 1.13.11.27) is also 
targeted by nitisinone (2-[2-nitro-4-(trifluoromethyl) benzoyl] 
cyclohexane-1,3-dione), which is used to treat HT1 (OMIM 276700) 
and is tested for AKU (Ranganath et al., 2018). 
HT1 is caused by 4-fumarylacetoacetate hydrolase (FAH, EC 3.7.1.2) 
deficiency, which is the last enzyme of the Phe-/Tyr-degradation 
pathway. Prior to this step is the cis-trans isomerization of 4-maleylace-
toacetate (MAAI, EC 5.2.1.2), which also occurs spontaneously or by 
alternative routes as MAAI deficiency gives no apparent symptoms other 
than the accumulation of fumarylacetoacetate and succinylacetone in 
the urine (Fernandez-Canon et al., 2002). The severity of HT1 results 
from the accumulation of toxic metabolites generated by the decom-
position of 4-fumarylacetoacetate; thus, inhibiting pathway upstream of 
HGD with nitisinone could relieve much of the extreme symptoms. 
However, this leads to a large increase in plasma Tyr levels as the re-
action catalyzed by TAT is reversible. The properties of TAT are not well 
studied, but it appears that the mammalian enzyme has a restricted 
substrate specificity, meaning that many AAs cannot replace glutamate 
or tyrosine. Thus, the relative abundance of the substrates and the 
enzyme kinetic constants will be important in determining the Tyr 
levels. There is reason to believe that species differences exist for TAT 
specificity and kinetics, which may influence the tolerance for aromatic 
AA disturbances in different animal models (Mehere et al., 2010; 
Sivaraman and Kirsch, 2006). 
3.2.2. Amino acid transport over the blood brain barrier 
Neurons and glial cells of the brain are surrounded by extracellular 
matrix and brain interstitial fluid (bISF), which has a different compo-
sition than plasma. The exchange of compounds between bISF and the 
brain microvasculature occurs over the BBB, which is maintained by 
tight junctions between the endothelial cells of the brain microvascu-
lature (Hawkins et al., 2006). In addition, there is an exchange occurring 
between the bISF and the cerebrospinal fluid (CSF), mainly over the 
ependymocytes of the ventricles and through the subarachnoid spaces 
(Tumani et al., 2017). The blood CSF barrier is maintained by epithelial 
cells of the choroid plexuses, where most of the CSF is generated. It is 
generally considered that the composition of the CSF and bISF is similar, 
although different barriers control much of the transport from plasma 
(Tumani et al., 2017). 
The BBB is of major importance for the transport of AAs into the bISF 
that must pass through both the luminal (towards the blood) and the 
abluminal (towards the brain) plasma membranes of the endothelium 
before reaching the basal membrane or matrix of the vasculature 
(Hawkins et al., 2006) (Fig. 1). In addition, extending processes from 
surrounding astrocytes and pericytes cover the basal membrane on the 
abluminal side, thereby further controlling transport. The barrier func-
tion is essential for several reasons, one being the differences in extra-
cellular AA levels in the brain relative to plasma (in CSF about 10 % for 
most AAs, 5 % for acidic AA, and about 80 % for glutamine) as many 
amino acids and their derivatives are vital neurotransmitters in the CNS. 
Similarly, monoamines are not transported across the BBB and must be 
synthesized from Tyr and Trp in the CNS. 
AAs are transported over the endothelial layer by specific trans-
porters located on both luminal and abluminal sides by facilitated pas-
sive transport, whereas Na+ dependent transporters located on the 
abluminal side only, pump AAs out of the brain (O’Kane and Hawkins, 
2003) (Fig. 1). Most essential AAs are transported into the brain by the 
same transporter system, i.e., the Large Neutral Amino Acid (LNAA) of 
the L1 type (LAT1, SLC7A5), and they are therefore mutually competing 
for transport into the brain. The LAT2 (SLC7A8) is prominent at the 
blood CSF barrier (Dolgodilina et al., 2020). The cationic amino acid 
transporter, referred to as the y + system, transports arginine, lysine, 
and ornithine with high affinity. However, in the presence of Na+, 
low-affinity transport of several non-basic amino acids, including Phe, 
also takes place by this transporter. 
The abluminal Na+ dependent transporters are key to maintaining 
the low AA levels in the brain. These transporters have somewhat 
overlapping substrate specificities, e.g., the Na + LNAA system, which 
transports all essential AAs except cysteine, has overlapping substrate 
specificity with the Alanine, Serine, Cysteine (ASC) preferring trans-
porter. However, only Na+ LNAA seems to transport aromatic AAs out of 
the brain (O’Kane and Hawkins, 2003). The endothelial cells of the BBB 
also have high γ-glutamyl transpeptidase activity and an active γ-glu-
tamyl cycle (Ogawa et al., 1998). This has been postulated to activate 
the Na + dependent abluminal AA transporters via its pyroglutamate 
intermediate. 
Since many AAs compete for the same transporter systems, distur-
bances in the balance of circulating AAs can affect their transport into 
the brain. Deficiencies of LAT1/SLC7A5 have been linked to ASDs 
(Tarlungeanu et al., 2016). In PKU, high serum Phe levels give rise to 
severe intellectual disabilities, growth retardation, and seizures if left 
untreated (see below). The highly elevated Phe can be expected to lower 
CSF Tyr and Trp levels. However, since they compete for both in- and out 
transport, their ratios may not be significantly shifted or event opposite 
(Antoshechkin et al., 1991; Lykkelund et al., 1988; Tanaka et al., 2006), 
depending on the kinetics of the transporter systems involved and the 
AA levels on either side of the barrier. Still, inhibited transport into the 
brain in addition to inhibition of AAAHs has been linked to lowered 
monoamine synthesis in the brain (Pilotto et al., 2019), and supple-
mentation with tyrosine has been shown to increase homovanillic acid 
(HVA), although individual responses are quite different (Lykkelund 
et al., 1988; Scala et al., 2020; van Vliet et al., 2019a). Still, even under a 
strict dietary regime, cognitive and neuropsychiatric symptoms are 
commonly observed. Today, a life-long low-Phe diet is recommended to 
keep the blood Phe levels between 2-6-fold (US) or <10 fold (Europe) 
that of normal levels (about 60 μM). Disorders of tyrosine metabolism 
can lead to highly elevated plasma levels of Tyr, such as in tyrosinemias 
(above), with elevated CSF Tyr levels (Thimm et al., 2011). 
Alterations of AA transport have also been described in other 
neuropsychiatric disorders, particularly ASDs where altered peripheral 
levels of the tryptophan-derived monoamine serotonin are among the 
best-documented biomarkers. As many ASD patients have ADHD 
symptoms or a diagnosis of ADHD, this connection is particularly rele-
vant. Missense mutations in subunits of the SLC3A2, SLC7A5, and 
SLC7A8 subunits of the LAT1 and LAT2 protein complexes have been 
observed in ASD patients (Cascio et al., 2020; Tarlungeanu et al., 2016). 
The effect of some of these mutations has been modeled in knockout 
mice, providing insights into their mechanisms (Tarlungeanu et al., 
2016). 
4. Clinical phenotypes in PKU, Tyrosinemias, and AKU 
As presented in Table 1b, reported cognitive symptoms are quite 
diverse, both between and within different NMDs. Likewise, in classical 
Mendelian diseases, the phenotypes are not only dictated by the primary 
metabolic defect but also by a wide range of modifying environmental 
and inherited factors, as well as their interactions. As such, discovering 
diffuse cognitive problems and recognizing them as part of the metabolic 
disorder (or its treatment), can be challenging. Still, awareness about the 
possible significant impact of such problems on, e.g., treatment adher-
ence (and thereby the prognosis for the metabolic condition itself) is 
important, especially since studies indicate that underdiagnosis of co-
morbid psychiatric conditions (“diagnostic overshadowing”) in somatic 
diseases are common (e.g., in neurological diseases) (Hendriksen et al., 
2015). 
4.1. PKU 
Irreversible neurological impairment, severe intellectual disability, 
stereotypy, and hyperactivity are reported in untreated PKU. Although 
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dietary treatment has improved outcomes, it is difficult to maintain full 
lifelong dietary control, and the risk of different psychiatric disorders is 
high, even with optimal maintenance. Attentional, mood and anxiety 
disorders are common, and a range of cognitive and neuropsychiatric 
changes at varying levels of hyperphenylalaninemia have been 
described (Ashe et al., 2019). In contrast to earlier beliefs, it is now 
increasingly recognized that maintenance of treatment (recommended 
Phe-values are between 120–360 μmol/L in the US and up to 600 μmol/L 
in Europe) also in adult age are associated with better psychosocial and 
cognitive outcomes. Nonetheless, these levels are still significantly 
higher than in individuals without PKU (Ashe et al., 2019). 
Neurodevelopmental problems described in diet-treated PKU are 
very similar to those described in ADHD, and in a study by Arnold, 26 % 
of children with PKU used stimulant medication for attentional 
dysfunction (Arnold et al., 2004). As in tyrosinemia, reduced motor 
function, attention, and working memory are reported (this is summa-
rized in a meta-analysis by (Stevenson and McNaughton, 2013)) in 
addition to lower executive functioning (Huijbregts et al., 2013) and 
lower social skills (Jahja et al., 2016). Normal IQ levels are reported in 
early-treated patients (infants); however, compared to siblings without 
PKU, these levels may be lower ((Berry et al., 1979; Diamond et al., 
1997; Dobson et al., 1976; Koch et al., 1984; O’Flynn and Hsia, 1968) in 
Diamond et al., 1997 (Diamond et al., 1997)). Diamond et al. found 
worse performance on executive functions (working memory and 
inhibitory control) in children with PKU whose Phe levels in plasma 
were three to five times higher than PKU children with lower levels, 
their siblings, matched controls, and children from the general popula-
tion (Diamond et al., 1997). This deficit seemed to influence the 
dorsolateral prefrontal cortex selectively, as performance on control 
tasks affecting other parts of the brain was similar to the control groups 
(Diamond et al., 1997). Berguig et al. found that lowering Phe in plasma 
to <360 μM increases neurotransmitters and 
neurotransmitter-metabolites to an almost normal range in PKU, in 
addition to reducing inattention symptoms (Berguig et al., 2019). This is 
in accordance with a study by Burton et al. where 20 % or more 
reduction in blood Phe levels were found in 57 % of subjects on sap-
ropterin, and both inattentive symptoms and executive function 
improved with this therapy (Burton et al., 2015). 
4.2. Tyrosinemias 
Several neurocognitive difficulties, as inattentiveness (Pohorecka 
et al., 2012), problems related to working memory and social cognition 
(van Ginkel et al., 2016), learning difficulties (Masurel-Paulet et al., 
2008), and lower IQ (Thimm et al., 2012), have been described in 
treated HT1. Such problems also occur in patients diagnosed with HT2 
or HT3. While tyrosine concentrations in HT3 patients are comparable to 
treated HT1 patients, HT2 patients display higher tyrosine levels and 
more prominent neurocognitive difficulties (Mitchell et al., 2001). 
Different mechanisms have been suggested to explain these problems, 
from sequelae from liver disease to toxic levels of Tyr. Van Vliet et al. 
found that high Tyr levels over the lifespan, especially the last year 
before testing, were related to internalizing behavior and health-related 
quality of life (van Vliet et al., 2019b). This is in line with a study 
showing correlations between inattentiveness and plasma levels of Tyr 
in treated patients with HT1 (Barone et al., 2020), with a stronger cor-
relation (r = .780) between recent levels of Tyr and inattention than long 
time levels (r = .707). However, separate pathways for different 
cognitive outcomes may be present within the same disorder. For 
instance, diagnosis of HT1 before eight months of age was related to a 
decline in IQ over time (Garcia et al., 2017), while this was not found in 
children diagnosed later. It has therefore been speculated (Barone et al., 
2020) if low IQ and symptoms of inattention in HT1 are affected by 
different pathways; one by the disorder itself (by affecting the vulner-
able infant brain), the other by its treatment (Barone et al., 2020). Van 
Ginkel et al. highlight that close monitoring of patients is important 
because of uncertain long-term effectiveness and new potential toxic-
ities of the treatment, (van Ginkel et al., 2019). 
In HT2 patients, intellectual deficit and neurological findings are 
identified in up to 60 % of cases. The intellectual deficit ranges from 
mild to severe and is the most common feature. Behavioral problems, 
nystagmus, tremor, ataxia, and convulsions have also been reported 
(Wendel, 2010). The full clinical spectrum of HT3, the rarest form of 
tyrosinemia, is unknown. Neurodevelopmental problems reported in 
these patients are summarized in a recent review by Barroso et al. and 
include ADHD, intellectual impairment, learning difficulties, dyslexia, 
behavioral disturbance, ataxia, microcephaly, and seizures (Barroso 
et al., 2020), but the classical phenotype is not yet established (Cerone 
et al., 1997; Ellaway et al., 2001; Russo et al., 2001). 
4.3. AKU 
This rare inherited metabolic disease affects the tyrosine metabolic 
pathway leading to the accumulation of homogentisic acid. Nitisinone 
reduces the accumulation of this metabolite, but the clinical implica-
tions are uncertain. Khedr et al. (2020) found that nitisinone increases 
Tyr not only in serum but also in tissues (Khedr et al., 2020), and it has 
been speculated if hypertyrosinemia could alter mood (Davison et al., 
2018). However, Davison et al. found no changes in monoamine neu-
rotransmitters in brain tissues when using a murine model of AKU where 
mice were treated with nitisinone (Davison et al., 2019). The authors 
suggested that hypertyrosinemia during nitisinone treatment does not 
affect the metabolism of monoamine transmission and, therefore, is 
unlikely to result in deficits in cognition and altered mood (Davison 
et al., 2019). In contrast, Harding et al. found an increase in dopamine 
by 36 % following nitisinone treatment in brain tissue, using a mouse 
model of PKU. This may be because Phe decreased by 44 %, possibly 
mediating inhibition of TH, thereby enabling dopamine biosynthesis 
(Harding et al., 2014). 
5. Clinical phenotype and biochemical mechanisms of other 
ADHD-related NMDs 
As briefly introduced in Section 2, several other NMDs (in addition to 
PKU, tyrosinemias, and AKU) present with ADHD and related behavioral 
phenotypes, such as SSADH deficiency, MSUD, XLI, MELAS syndrome, 
and MPS III syndrome. The known biochemical alterations of these 
disorders could shed light on ADHD pathophysiology; however, the 
details of these mechanisms and their effects on neurocognition are still 
unknown. This section provides an overview of the clinical phenotypes 
and biochemistry of the mentioned NMDs, and potential explanations 
for the many neuropsychiatric comorbidities observed. 
5.1. SSADH deficiency 
SSADH deficiency (OMIM 271980) is a disorder of γ-aminobutyric 
acid (GABA) metabolism caused by ALDH5A1 mutations (Jakobs et al., 
1981; Wang et al., 2019). A wide range of cognitive and related somatic 
features are present in SSADH patients, including ADHD (DiBacco et al., 
2019), mood and anxiety disorders (Gibson et al., 2003), and autistic 
behavior/ASD (Pearl et al., 2021, 2003a). Moreover, patients commonly 
present with additional symptoms, i.e., intellectual impairment 
(DiBacco et al., 2019; Pearl et al., 2021), obsessive-compulsion, irrita-
bility or aggression, hallucinations (Gibson et al., 2003; Pearl et al., 
2003a), hyperactivity, impulsivity (Gibson et al., 2003; Knerr et al., 
2008), language difficulties, and sleep disturbances (DiBacco et al., 
2019; Gibson et al., 2003). SSADH may be underdiagnosed because of 
the variable phenotype (Knerr et al., 2008). Research indicates wors-
ening of epilepsy, sleep, and behavioral disturbances (e.g., 
obsessive-compulsive behavior) with age (DiBacco et al., 2019), and 
Knerr et al. suggest that families of patients with SSADH deficiency need 
counseling and support about the anticipated persistence of 
S. Cannon Homaei et al.                                                                                                                                                                                                                      
Neuroscience and Biobehavioral Reviews xxx (xxxx) xxx
10
neuropsychiatric symptoms into adulthood (Knerr et al., 2008). 
As illustrated in Fig. 4, SSADH deficiency impairs the final step of 
GABA degradation where SSA is, under normal conditions, oxidized to 
succinic acid (succinate) and enters the tricarboxylic acid (TCA) cycle 
for energy utilization. Instead, the accumulated SSA is reduced to 
γ-hydroxybutyric acid (GHB) (Pearl et al., 1993). As a result, patients 
can have elevated levels of GHB (65-230-fold increase) and GABA (up to 
3-fold increase) (Gibson et al., 2003; Jakobs et al., 1981). SSADH ac-
tivity regulation coupled with increased levels of GHB and GABA can 
influence multiple CNS mechanisms through receptor dysfunction and 
possible neurotoxicity. With increased GHB, primary receptor activity 
shifts from presynaptic G-protein coupled GHB-receptors to GABAB re-
ceptors, consequently altering the presynaptic release of several 
important neurotransmitters (Kolker, 2018; Snead and Gibson, 2005). In 
addition, GHB elevation influences neurotransmitter release by 
depression of N-methyl-D-aspartate (NMDA) and α-amino-3--
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) 
receptor-mediated function (Berton et al., 1999). GHB and GABA ele-
vations also change MAP kinase activity through a GABA(B)R-mediated 
mechanism or by effects on myelination (Knerr et al., 2007; Kolker, 
2018). Murphy et al. found that 4-hydroxy-trans-2-nonenal (HNE), a 
major oxidative stress marker in neurodegenerative diseases, is mainly 
oxidized by SSADH in CNS mitochondria (Murphy et al., 2003). 
The behavioral problems observed in SSADH patients may result 
from altered dopamine and serotonin metabolism, as suggested by 
Gibson et al. and Pearl et al. (Gibson et al., 2003; Pearl et al., 2003b). 
The authors reported correlations between elevated GHB levels and the 
end-products of dopamine and serotonin metabolism: HVA and 
5-hydroxyindoleacetic acid (5-HIAA), respectively (Gibson et al., 2003; 
Pearl et al., 2003b). Likewise, increased levels of homocarnosine might 
influence the observed neurocognitive phenotype since other homo-
carnosine disorders (i.e., homocarnosinosis and GABA-transaminase) 
primarily present with neurological impairment ((Gibson and Jakobs, 
2001) in (Gibson et al., 2003)). The anticonvulsant Vigabatrin, an 
irreversible inhibitor of GABA transaminase (GABA-T), is (currently) the 
most common therapeutic intervention for SSADH patients. However, 
the clinical outcomes diverge, and, in some cases, patients show a 
neurological decline as it may aggravate the hyper-GABAergic status. 
Moreover, in vitro studies show that it could down-regulate SSADH 
activity. Hence, Vigabatrin should be used with caution (Knerr et al., 
2007). 
5.2. MSUD 
MSUD (OMIM 248600) is caused by mutations in one of three genes 
(BCKDHA, BCKDHB, DBT, resulting in mitochondrial branched-chain 
α-ketoacid dehydrogenase (BCKD) deficiency (Strauss et al., 1993). As 
shown in Fig. 5, the BCKD complex is responsible for the irreversible 
oxidative decarboxylation in the catabolism of branched-chain amino 
acids (BCAAs). Consequently, leucine (Leu), valine (Val), isoleucine 
(Ile), and their responding α-ketoacids (BCKAs; α-ketoisocaproic acid, 
α-keto-3-methylvaleric acid, and α-ketoisovaleric acid) accumulate 
rapidly (Strauss et al., 1993). MSUD patients are categorized into three 
subtypes based on enzyme activity levels: classic (most fatal), interme-
diate, and intermittent. A lifelong, protein-restricted diet is necessary to 
keep the plasma BCAA levels within the recommended ranges (Leu; 
75–200 μmol/L ≤ five years of age, 75–300 μmol/L > five years of age, 
Ile, Val; 200–400 μmol/L) (Frazier et al., 2014). 
MSUD-patients have increased prevalence of anxiety, depression, 
inattention, and impulsivity compared to controls, with a lifetime cu-
mulative incidence by age 36 years of 83 % for these conditions (Muelly 
et al., 2013). Patients remaining clinically asymptomatic during the 
newborn period were also compared with neonates that were enceph-
alopathic at diagnosis. The latter were five times more likely to suffer 
from anxiety and ten times more likely to suffer from depression, but not 
significantly more likely to suffer from ADHD. However, ADHD had a 
cumulative lifetime incidence of 54 % in MSUD patients on dietary 
therapy and 82 % on transplant treatment (Muelly et al., 2013). Results 
from this study are in line with a study by Strauss et al., showing that 
cognitive and psychiatric disabilities are not entirely prevented by di-
etary therapy or liver transplantation (Strauss et al., 2020). In a study by 
Abi-Wardé et al., negative psychiatric outcomes tended to be associated 
with higher Leu levels, highlighting the importance of compliance to 
dietary treatment (Abi-Warde et al., 2017). Strauss et al. also describe 
how constant BCAA fluctuations affect mechanisms related to several 
important neurophysiological processes. These processes include cere-
bral uptake of neurotransmitters, unbalanced amino acid transport 
across the BBB, continued neonatal encephalopathy, and disturbed 
Fig. 4. Overview of SSADH deficiency in the 
GABAergic synapse. GABA synthesis occurs 
when glutamate (Glu) is decarboxylated by 
glutamic acid decarboxylase (GAD) in the pre- 
synapse. In the synaptic cleft, GABA binds 
either the ionotropic receptors GABAA and 
GABAC, or the G-protein coupled receptor 
GABAB. After neurotransmission stops, GABA 
transaminase (GABA-T) converts GABA to suc-
cinic semialdehyde (SSA). SSADH deficiency 
impairs the oxidation of SSA to succinate, 
which then enters the tricarboxylic acid (TCA) 
cycle; therefore, SSA is reduced to γ-hydroxy-
butyric acid (GHB), resulting in the accumula-
tion of both GABA and GHB. The figure was 
made with Smart Servier Medical Art templates, 
licensed under a Creative Common Attribution 
3.0 License (https://smart.servier.com/).   
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energy metabolism and tricarboxylic acid flux (Strauss et al., 2020). 
Even though dietary treatment enriched with SLC7A5-substrates (Tyr, 
Phe, Trp, Met, His, and Thr) maintained the substrates plasma concen-
trations, the cerebral uptake of certain AAs (Trp, Glu, Met, and His) was 
25–34 % below the normal reference values (Strauss et al., 2020). 
In a recent review by Xu et al., the authors discuss the impacts of 
BCAA dysregulations on the neuropsychiatric phenotype observed in 
MSUD patients (Xu et al., 2020). For instance, low BCAA levels are 
frequently observed in ASD patients ((Arnold et al., 2003; Evans et al., 
2008; Garcia-Cazorla et al., 2014; Perry et al., 1978; West et al., 2014) 
reviewed in (Xu et al., 2020). Moreover, several studies propose a link 
between alterations in glutamate metabolism, decreased levels of 
N-Acetylaspartate (NAA), and elevated lactate to ADHD and 
ADHD-related symptoms, depression, anxiety, obsessive-compulsion 
disorder (OCD), and psychosis in MSUD patients (reviewed in (Xu 
et al., 2020). Low levels of precursors for monoamine neurotransmitters 
could also explain the clinical similarities between untreated PKU and 
MSUD patients (Xu et al., 2020), particularly comorbidities such as 
depression (Nutt, 2008), anxiety (Zarrindast and Khakpai, 2015), and 
ADHD (Doummar et al., 2018). 
The neurological impairment in MSUD patients could also be a result 
of inflammatory processes and oxidative stress. For instance, Scaini et al. 
reported that inflammation caused by high BCAA levels resulted in BBB 
breakdown (Scaini et al., 2014). Further, De Simone et al. showed that 
high BCAA levels modify the microglial immune properties, resulting in 
an intermediate M1 (pro-inflammatory)/M2 (anti-inflammatory) 
phenotype. A less efficient microglial response combined with increased 
free radicals may increase the susceptibility to neurodegeneration (De 
Simone et al., 2013). Likewise, clinical diagnostics show that, in some 
cases, patients suffer from antioxidant and L-carnitine (L-car) deficiency. 
However, whether this is a primary MSUD effect or secondary to 
insufficient nutritional intake is debated. In addition to maintaining 
energy balance, L-car modulates the mitochondrial transport of 
long-chain fatty acids and the following β-oxidation (Mescka et al., 
2015). 
5.3. XLI 
XLI (OMIM 308100) patients suffer from steroid sulfatase (STS) 
deficiency as a result of mutations in or complete deletion of (85–90%) 
the STS gene (Diociaiuti et al., 2019). In 2008 Brookes et al. reported an 
association between STS (SNP markers rs2770112 and rs12861247) and 
ADHD, making STS a candidate gene for ADHD susceptibility (Brookes 
et al., 2008). XLI may also be associated with ASD or related commu-
nication/language difficulties (Kent et al., 2008), in addition to epilepsy, 
motor disabilities, and mental retardation (Diociaiuti et al., 2019). 
However, ADHD seems to be the most common neurodevelopment 
disorder in XLI patients. In one study, 40 % fulfilled the DSM-IV criteria 
for ADHD, of which 80 % were categorized as the inattentive subtype 
(Kent et al., 2008). Other studies (Diociaiuti et al., 2019; Rodrigo-Ni-
colas et al., 2018) have found a prevalence of ADHD around 30 %. 
In addition to elevated ADHD prevalence, patients have a distinct 
somatic phenotype of dark-brown scaling, dry skin, increased skin 
permeability, hyperkeratosis, opacification of the corneal stroma, and 
cryptorchidism that appear during early infancy (Rodrigo-Nicolas et al., 
2018). Under normal conditions, STS cleaves sulfate groups from ste-
roids and sulfatases, e.g., cholesterol sulfate (CSO4) and dehydroepian-
drosterone sulfate (DHEAS). CSO4 plays a vital role in desquamation and 
alters the physical cell membrane properties, stabilizing cells in the 
stratum corneum (SC) (Elias et al., 2004). Epstein et al. (1984) introduced 
the epidermal CSO4 cycle, where CSO4 is sulphurated in the lower 
epidermis and desulphated in the outer epidermal layers regenerating 
cholesterol (Epstein et al., 1984). Consequently, STS may indirectly 
regulate steroid production in the granular layer of the epidermis 
(Hernandez-Martin et al., 1999). XLI patients can have up to ~50 % 
reduction of cholesterol content in the SC (Williams and Elias, 1981); 
however, several studies argue that subsequent permeability barrier 
abnormalities are caused by CSO4 accumulation rather than cholesterol 
deficiency (Zettersten et al., 1998). 
In contrast, DHEAS and dehydroepiandrosterone (DHEA) accumu-
lation are likely to influence the neuropsychiatric phenotype in XLI 
patients. These excitatory neurosteroids modulate GABAA and NMDA 
receptor activity and are known to alter biological and neurophysio-
logical processes in the CNS (Maayan et al., 2003). For instance, Strous 
et al. (2001) found an inverse correlation between clinical symptoms of 
ADHD, particularly hyperactivity, and DHEA blood levels, suggesting a 
protective effect of neurosteroids on ADHD symptom expression (Strous 
et al., 2001). Trent et al. (2013) later confirmed this correlation in a 
mouse model, arguing that DHEA’s influence on activity is particularly 
strong when encountering a novel environment (Trent et al., 2013). 
Further, treatment with standard medication for ADHD (methylpheni-
date) over three months was related to an increase in serum concen-
trations of DHEAS and DHEA in boys with ADHD, suggesting that the 
effects of methylphenidate may be partly related to these neurosteroids 
(Maayan et al., 2003). 
5.4. MELAS syndrome 
MELAS syndrome (OMIM 54000) is a mitochondrial, multisystem 
disorder most frequently caused by MT-TL1 mutations (m.3243A > G), 
decreasing the metabolic stability of tRNALeu(UUR) (Chomyn et al., 2000; 
El-Hattab et al., 2015). This results in impaired mitochondrial trans-
lation, subsequent decrease in the electron transport chain (ETC) sub-
unit synthesis, and, thus, lack of sufficient ATP production (El-Hattab 
et al., 2015). Although this mechanism is debated, MELAS patients are 
reported to have specific alterations of neurological functions instead of 
global neurological impairment (Kraya et al., 2019). Kraya et al. found 
particular deficits in executive functioning, attention, visuoperception, 
and construction (Kraya et al., 2019). These cognitive changes were 
significantly correlated with everyday life disturbances and high scores 
Fig. 5. Overview of BCAA catabolism in MSUD patients. First, BCAAs are 
transported into liver cells by the L-transporter. Second, they are either (1) 
converted to BCKAs by branched-chain amino acid transaminase (BCAT) 1 and 
transported into the mitochondria by the BCKA transporter, or (2) transported 
into the mitochondria directly by the mitochondrial carrier family (MCF) and 
then converted to BCKAs by BCAT-2. Third, the branched-chain α-ketoacid 
dehydrogenase (BCKD) complex facilities complete BCKA degradation to 
succinyl-CoA and acetyl-CoA, which then enters the tricarboxylic acid (TCA) 
cycle. Hence, MSUD patients with deficient BCKD complex will rapidly accu-
mulate BCAAs and BCKAs. The figure was made with Smart Servier Medical Art 
templates, licensed under a Creative Common Attribution 3.0 License (https:// 
smart.servier.com/). 
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on the Newcastle Mitochondrial Disease Adult Scale (NMDAS) (Schaefer 
et al., 2006), measuring the severity of the syndrome. Similarly, Near-
garder et al. reported deterioration in executive functioning, language, 
attention, memory, visuospatial, and motor functioning in two MELAS 
cases (Neargarder et al., 2007). It has been suggested that mitochondrial 
disorders are underdiagnosed in psychiatric patients. Thus, Anglin et al. 
reported that anxiety, psychosis, cognitive deterioration, and mood 
disorders were the most common psychiatric presentations in 50 cases 
with mitochondrial disorders, of which 52% had a MELAS mutation 
(Anglin et al., 2012). 
Kraya et al. also reported a significant correlation between clinical 
symptoms and higher lesion load, suggesting that the cognitive pheno-
type in MELAS is partially caused by degeneration and metabolic al-
terations (Kraya et al., 2019). A predominant feature of MELAS is the 
stroke-like episodes related to dysregulation of NO synthesis and mito-
chondrial proliferation that influence the availability of NO and its 
precursors (citrulline, arginine). The resulting NO deficiency can cause 
impaired blood perfusion in the microvasculature (Fig. 1, Section 4) 
(reviewed in (El-Hattab et al., 2015)). As reviewed in El-Hattab et al., 
the fluctuation in NO levels, and resulting in impaired NOS activity, 
could also be caused by reactive oxygen species (ROS) overproduction, 
increased oxidative stress, and subsequent increased levels of the 
endogenous NOS inhibitor asymmetric dimethylarginine (AMDA) 
((El-Hattab et al., 2014, 2012; Teerlink et al., 2009) in (El-Hattab et al., 
2015)). 
The accumulation of cortical injuries obtained during stroke-like 
episodes could influence the neurocognitive phenotype observed in 
patients ((Sproule and Kaufmann, 2008) in (El-Hattab et al., 2015). 
Hence, it is not clear if the neuropsychological impairment in MELAS 
syndrome is caused by stroke-like episodes only or also by neuro-
degeneration or energy production (Kraya et al., 2019). In addition, MR 
studies show a correlation between the degree of neurological impair-
ment and elevated lactate levels; patients also had decreased levels of 
NAA (Cakmakci et al., 2010). These findings are consistent with those in 
MSUD (Section 4.2), connecting NAA and lactate levels to depression, 
anxiety, and ADHD (reviewed in (Xu et al., 2020)). 
5.5. MPS III (Sanfilippo syndrome) 
MPS III, known as Sanfilippo syndrome, is a lysosomal storage dis-
order. It is divided into four subcategories depending on the genetic 
mutation; (1) MPS IIIA (SGSH gene), (2) MPS IIIB (NAGLU gene), (3) 
MPS IIIC (pericentromeric region of chromosome 8p11.12), and (3) MPS 
IIID (GNS gene) (reviewed in (Andrade et al., 2015)). As a result, pa-
tients have; (1) heparan-N-sulfatase (HS), (2) α-N-acetylglucosamini-
dase, (3) α-acetylglucosaminidase transferase, or (4) 
N-acetylglucosamin-6-sulfatase deficiency (Zhou et al., 2020). These 
enzymes all participate in the degradation of heparan sulfate (HS), a 
proteoglycan, thus affecting cell homeostasis and signaling pathways 
(Andrade et al., 2015). Compared to MPS I (Hurler syndrome) and MPS 
II (Hunter syndrome), where somatic symptoms such as facial dys-
morphism are extensive, MPS III primarily presents with neurological 
deficits (Wijburg et al., 2013). 
MPS III patients have a distinct neuro(psychiatric) phenotype that 
gradually develops; most patients display symptoms between age 2 and 
6. Wijburg et al. reported that patients are often initially misdiagnosed 
with ADHD or ASD due to symptoms of hyperactivity, impulsivity, 
aggression, and extreme restlessness (Wijburg et al., 2013). In addition, 
sleep disorders, mood and anxiety disorders, language issues, 
obsessive-compulsion, and mental retardation are observed in these 
patients (Andrade et al., 2015; Hoffmann et al., 2020; Kong et al., 2020; 
Montenegro et al., 2021; Wijburg et al., 2013; Zhou et al., 2020). 
Magnetic resonance imaging (MRI) studies show that patients have se-
vere neurological degeneration and distinct morphological changes, 
such as ventriculomegaly or symptomatic hydrocephaly. Andrade et al. 
reported that the degree of ventricular dilation is linked to the severity 
of mental retardation (Andrade et al., 2015). Further, the degree of 
neurocognitive impairment (and neuropathology) is dependent on the 
type of MPS III. For instance, the prevalence of behavior problems is 
higher in patients diagnosed with MPS IIIA, which is the most frequent 
type of MPS III (60 %) (reviewed in (Andrade et al., 2015)). 
5.6. Other conditions 
As mentioned, ADHD-related NMDs are not limited to the disorders 
described above (Sections 3.2.1, 4, and 5). For instance, Fraidakis et al. 
reported a 12.5 % incidence of psychiatric manifestations in cere-
brotendinous xanthomatosis (CTX) patients found in the literature be-
tween 1937 and 2012, where behavior problems accounted for 5.6 % 
(Fraidakis, 2013). This is a rare autosomal recessive disorder of the bile 
acid synthesis which is associated with elevated levels of cholestanol in 
blood and cholestanol and cholesterol in the brain, bile and tendons. 
Clinical manifestations include neurologic dysfunction, in addition to 
chronic diarrhea, bilateral cataracts and tendon xanthomas (Salen and 
Steiner, 2017). Attentional problems, including ADHD, could be the 
presenting symptoms in young children (Fraidakis, 2013). Similarly, 
ADHD and behavioral problems are observed in urea cycle disorders 
(Serrano et al., 2010). In albinism, which comprises diseases charac-
terized by impairment of the melanin synthesis, ADHD was found in 22, 
7% of children and 6,8% of adults (Kutzbach et al., 2007). Iwański et al. 
(Iwanski et al., 2015) showed problems in several aspects of attention in 
patients with Wilson’s disease (rare inherited disorder where copper 
accumulate in the body) with neurological symptoms, and an isolated 
deficit in sustained attention in neurologically asymptomatic patients. 
Another relevant disorder is MAO deficiency, also described in Section 
3.1. In their review, Bortolato and Shih (Bortolato and Shih, 2011) 
argued that variations in enzymatic activity of MAO may influence 
behavioral regulation and be involved in a spectrum of mental disorders, 
such as autism and ADHD. Creatine transporter deficiency is charac-
terized by several clinical symptoms, such as epilepsy, motor dysfunc-
tion, gastrointestinal symptoms, developmental delay, intellectual 
disability and autism, in addition to ADHD (Farr et al., 2020). In Cys-
tathionine β-synthase deficiency, psychiatric complications, including 
symptoms of hyperactivity, were found in 51 % of adults (Abbott et al., 
1987). Hyperactivity has also been reported in β-mannosidosis (Bedilu 
et al., 2002). In addition, ADHD-like symptoms have been mentioned 
sporadically in several other metabolic disorders (Dinopoulos et al., 
2005; Sedel et al., 2007), but this falls without the scope of the present 
paper. 
6. Clinical implications 
In our review, we have summarized (a) NMDs reported to be asso-
ciated with an increased prevalence for ADHD and (b) which molecular 
mechanisms might underly such comorbidity. This knowledge is inter-
esting from a pathophysiological perspective and should also aid in 
identifying novel treatments and provide personalized care. However, 
knowledge about the connection between NMDs and ADHD is also 
relevant on a very practical level for the clinician. 
For clinicians involved in managing metabolic and/or neuropsychi-
atric disorders, knowledge of their relationships is crucial in several 
settings. These include the optimization of treatment plans for persons 
with known metabolic diseases, screening for possible underlying 
metabolic diseases, as described here, in persons with (atypical) 
neuropsychiatric symptoms, and systematically collecting genotype- 
phenotype data that can increase our knowledge base of these connec-
tions and pave the way for improved future diagnosis and treatment. 
The complex relationship between NMDs and (neuro)psychiatric 
difficulties, as described above, illustrates that somatic and mental 
health are deeply intertwined and that there is a need for broad, inter-
disciplinary assessments to prevent overlooking important symptoms. 
For example, Hendriksen et al. have suggested that somatic features 
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could overshadow ADHD in neurological diseases (Hendriksen et al., 
2015). This may also be the case in metabolic disorders, as fear of death 
and serious complications from the metabolic disorder could be part of 
daily life both for patients and their closest family members and move 
focus away from cognitive difficulties. In line with this hypothesis, it has 
been speculated if parents of children with Tyrosinemia type 1 system-
atically underreport attention problems in their children because diffuse 
cognitive problems may be overlooked in the presence of serious so-
matic concerns (Barone et al., 2020). Paradoxically, this could lead to an 
underdiagnosis of ADHD, thereby adding problems with managing the 
strict treatment regime required for the metabolic disorder. This hy-
pothesis is supported by a study showing poor treatment adherence in 
adolescents with type 1 diabetes and undiagnosed ADHD (Nylander 
et al., 2018). 
Because of the possible underreporting of symptoms, the symptom 
load from ADHD may need to be higher to be detected in patients with 
NMDs. This is very unfortunate, as unrecognized ADHD may be more 
harmful in this patient group, because of higher dependency on func-
tions that are compromised by their ADHD symptoms. Thus, even 
symptoms below the conventional diagnostic threshold for ADHD may 
cause significant problems with treatment adherence. Therefore, 
focusing on dimensional traits, such as relevant executive functions and 
attention, may be a more fruitful approach than only focusing on cate-
gorical diagnoses. 
Clinical phenotypes of metabolic disorders are cutting across tradi-
tional diagnostic boundaries. Overlapping symptoms of different 
(neuro)psychiatric conditions are common (see Table 1b). The dimen-
sional nature and overlapping symptoms in (neuro)psychiatric disorders 
could lead to both over- and underdiagnosis of these conditions. As an 
example of possible overdiagnosis, Arvidsson et al. reported that fewer 
symptoms are required to get a diagnosis of autism today than previ-
ously. They suggested that the impairment in cases with less obvious 
symptoms of autism may stem from other "comorbid" problems, like 
ADHD (Arvidsson et al., 2018). They also suggested that individuals 
with complex constellations of psychiatric problems, but without a 
"correct" diagnosis (as autism), could risk being denied community 
support and that this may be part of the explanation for the rise in di-
agnoses in the autism spectrum. Such “strategic” categorical misdiag-
nosis of (neuro)psychiatric conditions could lead to biased conclusions 
about their relationships with metabolic disorders, while examining 
dimensional functions may increase the knowledge about metabolic and 
(neuro)psychiatric disorders across diagnostic boundaries. The assess-
ment of dimensional functions across different disorders would also 
make it possible to include a higher number of participants, as many 
patients may not fulfill the criteria for a specific diagnosis but still have 
significant symptoms. Increased participant size could be especially 
important in rare metabolic diseases, where the literature is dominated 
by case studies that carry an inherent the risk of publications bias to-
wards positive findings. 
Although it could be preferable to evaluate cross-diagnostic, 
dimensional cognitive deficits, like executive function (EF) problems 
in NMDs, such problems could also be difficult to recognize. It has been 
suggested that ADHD primarily is a disorder of EF (Barkley and Murphy, 
2010). Still, when using standard neuropsychological tests, impairment 
in executive functioning is only found in a minority of the cases (Bie-
derman et al., 2006; Nigg et al., 2005). It is uncertain if this is because EF 
deficits only exist in a subgroup of patients with ADHD or if it is due to 
the low ecological validity of the neuropsychological tests used to assess 
these functions. The latter hypothesis is supported by studies showing 
that scores on neuropsychological tests of EF only modestly predict 
behavioral EF performance (Krieger and Amador-Campos, 2018) and 
that questionnaires and tests measure different underlying constructs of 
EF (Chevignard et al., 2012). Some researchers, therefore, suggest that a 
combination of EF tests and questionnaires may be the optimal way to 
assess EF as they provide complementary information (Barkley and 
Murphy, 2010; Krieger and Amador-Campos, 2018). 
Broad assessments, including questionnaires, neuropsychological 
tests, and clinical interviews where potential cognitive difficulties are 
assessed, may be necessary to recognize the full range of cognitive dif-
ficulties in this heterogeneous group of diseases. In addition to parents, 
teachers, employers, or other people close to the patient could also 
provide useful information, as they may have a different point of 
reference. A closer collaboration across somatic and psychiatric health 
care in combination with increased consciousness and knowledge about 
ADHD, the nature of EF, and other cognitive functions, in addition to 
awareness about metabolic disorders in psychiatric health care, may 
also facilitate a comprehensive understanding of the complex in-
teractions between somatic, cognitive, and (neuro)psychiatric diffi-
culties. To identify these patients and their wide range of different 
symptoms, clinicians must be open-minded and look for them both in 
somatic and psychiatric health care. 
Clinicians treating NMDs need to be aware that such conditions 
could be accompanied with ADHD and related neuropsychiatric disor-
ders. This calls for proactive screening of affected children, especially 
during the first decade of life, with a subsequent in-depth assessment if 
screening positive. In this respect, both clinician case ratings, parent and 
teacher reports should be considered. Given that some NMDs require 
strict, life-long, and demanding dietary interventions, ADHD treatments 
targeting impulsivity and inattention might also enable patients to 
obtain better self-control; interventions that ultimately could improve 
the long-term outcome of NMDs. Still, potential beneficial effects of 
stimulant medications should be weighed against possible interactions 
with the core metabolic disturbances and somatic symptoms of the 
NMDs. 
Another clinical scenario is that unrecognized NMDs are present in 
children presenting primarily with ADHD symptoms. Although the risk 
that the classical NMDs mentioned above go undetected is rather low, 
milder variants with non-Mendelian genetic transmission could be 
overlooked. Because of the possible underreporting of symptoms and 
diagnostic overshadowing, it is possible that cognitive deficits in 
metabolic disorders are more common than previously estimated and if 
that the recommended levels of e.g., tyrosine and phenylalanine should 
be even stricter. A more conservative approach may prevent cognitive 
problems that are difficult to recognize using traditional neuropsycho-
logical tests and questionnaires but still lead to significant impairments 
in daily life. Therefore, we call for increased awareness of the NMD- 
ADHD comorbidity in primarily (neuro)pediatric settings. In this 
context, close collaboration between pediatrics, child and adolescent 
psychiatry, and later in life the respective adult services, is crucial. 
Grand case rounds, case reports, journal clubs, and related clinical ed-
ucation may be instrumental in fostering better education and 
interdisciplinarity. 
To conclude, NMDs often produce behavioral symptoms or syn-
dromes indistinguishable from (idiopathic) neuropsychiatric disorders, 
including ADHD. Irrespective of their etiology, such symptoms need to 
be adequately diagnosed and treated. Beyond these practical implica-
tions, it has been debated whether such comorbid manifestations of a 
metabolic disease should be termed ADHD as well, or rather ADHD-like 
syndrome, secondary ADHD, or similar. At the moment, this is a rather 
semantical question that can only be resolved when the pathophysiology 
of idiopathic ADHD is known, so we can evaluate whether NMD- 
associated ADHD has shared or distinct mechanisms of disease. 
Together, NMDs constitute a large and heterogenous group of con-
ditions with a range of severities and possibly involving many different 
biological mechanisms. In addition to explaining mechanisms of NMDs, 
the elucidation of such underlying mechanisms may help uncover ADHD 
pathophysiology in general and provide fundamental biological in-
sights. Here we have mainly focused on NMDs that directly interfere 
with the production, transport, or metabolism of amino acid or mono-
amine neurotransmitters/neuromodulators. As catecholamines appear 
to be of primary importance in the action of stimulants and other drugs 
that are used to treat ADHD, it is striking that NMDs that inhibit the 
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synthesis of catecholamines also produce ADHD-like symptoms. 
7. Implications for research 
This review has revealed several problems that need to be addressed 
in future research. First, there are strong indications of publication bias 
in the existing literature. Although ADHD symptoms are common in the 
general population, particularly in clinical samples, systematic exami-
nation and reporting of such symptoms are often missing in the clinical 
literature. For instance, although ADHD is often comorbid with ASD, 
learning disorders, and intellectual disabilities, many studies fail to 
include and report how ADHD was assessed in these patient groups. 
Thus, the overview of clinical features listed in Tables 1a and 1b are by 
no means comprehensive or exhaustive. Skewed or missing information 
will inevitably lead to a systematic bias in prevalence rates, with 
negative implications for guidelines and clinical practice. 
Historically all the rare metabolic diseases described here were 
discovered using various targeted laboratory tests in small clinical 
samples with striking clinical phenotypes and Mendelian patterns of 
inheritance. However, this procedure may gradually be replaced with a 
more systematic approach, including next-generation metabolic 
screening. Thus, the –omics revolution has paved the way for examining 
metabolic aberrations in many traits and clinical conditions, including 
conditions with less striking phenotypes and lower penetrance. 
As the available sample sizes and significance of GWA studies 
examining ADHD and related traits keep growing, these data sources 
should be systematically examined to explore the contribution of com-
mon variants of small effects to metabolic pathways. Such studies are 
needed to determine the role of polygenic alterations affecting meta-
bolic pathways in complex, multifactorial neuropsychiatric disorders, 
beyond the classical NMDs mentioned in this review. So far, our insights 
into the pathophysiology of NMDs have often been limited to the use of 
surrogate measurements such as blood biomarker profiles. With the 
introduction of more sensitive, non-invasive technologies, such as brain 
magnetic resonance spectroscopy (MRS), functional magnetic resonance 
imaging (fMRI), positron emission tomography (PET), or functional 
near-infrared spectroscopy (fNIRS), it is possible to measure biochem-
ical alterations and neurotransmitter receptors and transporter levels 
directly in intact brain tissue of patients and to correlate such mea-
surements with their clinical manifestations. These approaches may be 
combined with computational methods to handle high dimensional, 
heterogeneous data types and systems biology modeling, e.g., genome- 
scale metabolic models (Berndt et al., 2020; Brunk et al., 2018). Sys-
tems medicine approaches may help uncover hidden relationships be-
tween genetic variants, metabolic deviations, and neuropsychiatric 
symptoms. Such studies may have important clinical implications. 
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